In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Teva licenses Active Biotech's laquinimod; Active later regains rights

Executive Summary

Israeli-based Teva Pharmaceutical Industries Ltd. has been granted the exclusive worldwide rights to develop, manufacture, and market Active Biotech AB's (autoimmune and inflammatory diseases and cancer) laquinimod, an immunomodulatory drug candidate for multiple sclerosis. Active Biotech is keeping rights to the Nordic countries and Baltic states of Lithuania, Latvia, and Estonia.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Concluded
Deal Type
  • Alliance
    • Includes Royalty or Profit Split Information
    • R&D and Marketing (Licensing)

Related Companies